PARP1 and breast carcinoma: Early clinical results with the PARP1 inhibitor iniparib (BSI-201) in 123 patients with TN breast cancer were encouraging and showed that the addition of iniparib to treatment with gemcitabine plus carboplatin significantly increased median overall survival (OS, 12.3 versus 7.7 months; P = 0.01), median progression-free survival (PFS, 5.9 versus 3.6 months; P = 0.01), and objective response rate (ORR, 52% versus 32%; P = 0.02) [20].